World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 16 November 2020
Main ID:  EUCTR2019-003964-30-GB
Date of registration: 31/07/2020
Prospective Registration: Yes
Primary sponsor: Cambridge University Hospitals NHS Foundation Trust
Public title: Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory vasculitis in adults and children.
Scientific title: Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children - Biologics in refractory vasculitis (BIOVAS)
Date of first enrolment: 22/10/2020
Target sample size: 140
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003964-30
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: yes Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: yes Other: no Number of treatment arms in the trial: 24  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. Aged at least 5 years
2. Have given, or their parent/ legal guardian aged = 16 years old has given, written informed consent
3. Diagnosis of NAAV
4. Refractory disease defined by:
- Active disease, BVAS v3 modified for BIOVAS (BVAS v3-BIOVAS)/ PVAS with = 1 severe (new/worse) or =3 non-severe (new/worse) items despite 12 weeks of conventional therapy prior to screening visit (OR)
- Inability to reduce prednisolone below 15mg/day or (0.2mg/kg/day in case of children) without relapse in the 12 weeks prior to screening visit

Are the trial subjects under 18? yes
Number of subjects for this age range: 14
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 91
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 35

Exclusion criteria:
1. Previous treatment failure/contraindication to = 2 active trial IMPs
2. Increase in the dose or frequency of background immunosuppressive (e.g. methotrexate) or anti-cytokine therapy within 30 days of screening visit
3. Use of plasma exchange or intravenous immunoglobulins within 30 days, or cyclophosphamide or lymphocyte depleting biologic (e.g. rituximab) within 6 months of screening visit
4. Have an active systemic bacterial, viral or fungal infection, or active/latent tuberculosis
5. Hepatitis B (HB) core antibody (Ab) or HB surface antigen positive or hepatitis C antibody positive or human immunodeficiency virus (HIV) antibody test positive
6. History of malignancy within five years prior to screening visit or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure
7. Pregnant or breastfeeding
8. Severe disease, which in the opinion of the physician prevents randomisation to placebo
9. Recent or upcoming major surgery within 45 days of screening visit
10. Leukocyte count < 3.5 x 10^9, platelet count < 100 x 10^9 cells/l, neutrophil count of < 1 x 10^9 cells/l
11. ALT or ALP > 3 times the upper limit of normal
12. Symptomatic congestive heart failure (NYHA class III/IV) requiring prescription medication within 90 days of screening visit
13. Demyelinating disorders
14. History or presence of any medical condition or disease which, in the opinion of the Investigator, may place the participant at unacceptable risk because of trial participation
15. Administration of live or live attenuated vaccines within 45 days of screening
16. Participation in any clinical trial of an investigational medicinal product within 30 days prior to screening or within 5 half-lives after taking the last dose
17. Diagnosis of adenosine deaminase type 2 (DADA2)
18. Hypersensitivity to the active IMP substance or to any of the formulation excipients


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Non-ANCA associated vasculitides: 1. Giant cell arteritis (GCA) 2. Takayasu’s arteritis (TA) 3. Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN) 4. Relapsing polychondritis (RP) 5. IgA vasculitis (IgAV) 6. Cogan’s syndrome 7. Non-infective cryoglobulinaemia 8. Primary angiitis of central nervous system (PACNS)
MedDRA version: 21.1 Level: PT Classification code 10047115 Term: Vasculitis System Organ Class: 10047065 - Vascular disorders
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Intervention(s)

Product Name: Infliximab
Product Code: N/A
Pharmaceutical Form: Powder for concentrate for solution for infusion
INN or Proposed INN: Infliximab
CAS Number: 170277-31-3
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Trade Name: Rituximab
Product Name: Rituximab
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Rituximab
CAS Number: 174722-31-7
Concentration unit: g gram(s)
Concentration type: up to
Concentration number: -1
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Trade Name: Tocilizumab
Product Name: Tocilizumab
Product Code: N/A
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Tocilizumab
CAS Number: 375823-41-9
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: range
Concentration number: 4-10
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)
Main Objective: How clinically effective are the following biologic treatments: Infliximab, Rituximab and Tocilizumab compared to placebo in treating refractory non-ANCA associated vasculitis?
Primary end point(s): Primary outcome is time to treatment failure (TTF).

TTF for each IMP is the time from the start of IMP treatment, to treatment failure (see definitions below) or the end of trial participation (censored).

Primary treatment failure is progressive disease (defined by appearance of =1 new/worse severe or =3 new/worse non-severe items) on Birmingham vasculitis activity score (BVAS) v3 modified for BIVOAS (BVAS v3-BIOVAS) or paediatric vasculitis activity score (PVAS) within 120 days from the time of IMP commencement; or failure to achieve clinical response (see definitions below) by 120 days from the time of IMP commencement. In such cases, TTF will be recorded as zero.

Secondary treatment failure is defined as having achieved response by 120 days from IMP commencement, with subsequent relapse (see definitions below) after 120 days from IMP commencement.

If an adverse reaction to an IMP precludes the participant from receiving further doses of the trial drug, this will also be considered a secondary treatment failure .

The primary outcome for each active IMP is pooled across all participants in the primary group and compared against placebo.

Response is defined by:
Absence of new/worse BVAS v3 modified for BIOVAS (BVAS v3-BIOVAS) (adults) / PVAS (children) items assessed at the 120 day evaluation time points after commencing IMP AND
Prednisolone = 10mg/day or = 0.2 mg/kg for children (whichever is lower), unless the baseline dose is < 10mg/day or < 0.2 mg/kg children (whichever is lower) in which case it should not be more than the baseline dose*.
* Baseline dose is the dose of oral prednisolone, mg/day, or equivalent steroid, averaged over the 7 days prior to the start of each new IMP .

Relapse is defined by either:
Appearance of = 1 severe (new/worse) or = 3 non-severe (new/worse) BVAS v3 BIOVAS/PVAS items from the time of BVAS response (as defined above) assessed at the 120 day evaluation time points# OR
The need to increase the dose of prednisolone to > 20mg/day to treat vasculitis OR
The need to increase the dose of an immunomodulator or immune-suppressive therapy in order to treat vasculitis

# Non-severe items can be upgraded by the investigator to severe based on their potential clinical impact, e.g. headache in GCA, thus could meet failure criteria if only one or two items are present.
Secondary Objective: How safe, clinically effective and cost-effective are these treatments in comparison to each other and placebo?
Timepoint(s) of evaluation of this end point: Participants will be assessed for primary outcome measure every 120 days.
Secondary Outcome(s)
Secondary end point(s): 1. Bayesian hierarchical priors elicitation for treatment effects of biologics compared to placebo and biologics against each other in 2 groups: large vessel vasculitis (GCA/TA) and all other NAAV subgroups in the study
2. Proportion of patients achieving response at 120 days evaluation after the start of each intervention.
3. Proportion of patients achieving response at 120 days defined by a BVAS v3/ PVAS of = one non-severe (no new/worse) item, prednisolone dose = 50% of the dose at the start of the intervention and = 10mg/day (0.2 mg/kg/day for children, whichever is lower) and an ESR < 30mm/hr or CRP <10 mg/L
4. Increase in disease related damage measured by VDI/PVDI from start to end of an IMP block
5. Physician’s global assessment (PGA) (Likert scale 0-10) every 120 days
6. Serious adverse events/Serious adverse reactions (SAEs/SARs)
7. EQ-5D-5L or Child Health Utility (CHU9D) assessments every 120 days
Timepoint(s) of evaluation of this end point: Participants will be assessed for secondary outcome measures every 120 days.
Secondary ID(s)
BIOVAS
ISRCTN16502655
Source(s) of Monetary Support
National Institute for Health Research
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 22/10/2020
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history